In a nutshell The study evaluated outcomes of brigatinib (Alunbrig) versus crizotinib (Xalkori) in patients with non-small cell lung carcinoma (NSCLC) and anaplastic lymphoma kinase (ALK) mutations, who were previously not treated with ALK inhibitors (ALKI). The main finding was that brigatinib had better long-term outcomes compared to crizotinib in such...Read More
Current disease status-Recurrent cancer Posts on Medivizor
Does durvalumab with or without tremelimumab offer potential as a third line or later treatment of advanced non-small-cell lung cancer?
In a nutshell This study assessed whether patients with metastatic non-small-cell lung cancer (mNSCLC) would benefit from treatment using durvalumab (Imfinzi) with or without tremelimumab (CP-675,206) as a later treatment. The authors concluded that durvalumab showed improvement in overall survival (OS) and...Read More
Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer
In a nutshell The study compared the long-term effects of moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) and conventionally fractionated IMRT (C-IMRT) on outcomes in patients with localized prostate cancer (PC). The authors found that H-IMRT was similarly effective compared to C-IMRT after 10 years of therapy in such...Read More
Does olaparib increase survival in patients with metastatic castration-resistant prostate cancer?
In a nutshell This study assessed whether olaparib (Lynparza) affected progression-free survival (PFS; survival without cancer worsening) in patients with metastatic castration-resistant prostate cancer (mCRPC) and certain genetic mutations (abnormalities). The study found that olaparib improved PFS in these patients. Some...Read More
Can pembrolizumab combined with chemotherapy slow the progression of extensive stage small-cell lung cancer?
In a nutshell The study evaluated the addition of pembrolizumab (Keytruda) to etoposide (Etopophos) and platinum chemotherapy drugs for patients with untreated extensive-stage (ES) small-cell lung cancer (SCLC). The study found that pembrolizumab improved progression-free survival (PFS; survival without cancer getting worse) when added to...Read More
Abemaciclib plus trastuzumab for advanced HER-2 positive breast cancer
In a nutshell This study looked at abemaciclib (Verzenio), trastuzumab (Herceptin), and fulvestrant (Faslodex) for the treatment of advanced hormone-receptor-positive (HR+) and HER2 positive (HER2+) breast cancer. It found that this treatment led to better outcomes than standard-of-care chemotherapy for these patients. Some background Worldwide,...Read More
Do biological drugs work better alone or in combination with other drugs for patients with advanced non-small cell lung cancer who previously received treatment?
In a nutshell This study compared if anti-PD-1 biological drugs were more effective alone or when used with other drugs to treat patients with advanced non-small cell lung cancer who had previously received treatment. The results showed that the combination of anti-PD-1 and other drugs such as chemotherapy improved patients’ survival more than...Read More
The role of androgen deprivation therapy plus radiotherapy in the treatment of prostate cancer after prostate surgery
In a nutshell This study compared the safety and effectiveness of short-term androgen deprivation therapy (ADT) combined with radiotherapy (RT) in patients who underwent radical prostatectomy (RP). The main finding was that the combination of ADT and RT reduced the risk of recurrence and disease progression in these patients. Some background RP is...Read More
Evaluating the long-term outcomes of pembrolizumab versus ipilimumab for advanced melanoma
In a nutshell This study compared the long-term outcomes of two targeted therapies for patients with advanced melanoma. This study concluded that pembrolizumab (Keytruda) was more effective than ipilimumab (Yervoy) for these patients, with a similar rate of side effects. Some background Advanced melanoma is a type of skin cancer...Read More
Evaluating osimertinib for elderly patients over age 80 with advanced NSCLC
In a nutshell This study evaluated the effectiveness of osimertinib (Tagrisso) in patients over age 80 with advanced small cell lung cancer (NSCLC). This study found that these elderly patients had similar outcomes to patients in clinical trials. Some background NSCLC is the most common type of lung cancer. One common treatment is...Read More
Second-line therapy for lung cancer – which is most effective?
In a nutshell This study investigated second-line treatments for non-small cell lung cancer (NSCLC). They found that second-line options are effective in advanced NSCLC. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Many cases of NSCLC are diagnosed at an advanced stage. First-line treatment...Read More
Searching for men relapsed prostate cancer to test a treatment combination
In a nutshell This trial is looking at blocking androgens (male sex hormones) with different medications in men with raised PSA (a blood marker of prostate cancer) levels after prostate surgery. The main outcome to be measured will be the length of time the patients survive without the cancer progressing. This study is being conducted in the United...Read More